<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406286</url>
  </required_header>
  <id_info>
    <org_study_id>156-402-00110</org_study_id>
    <nct_id>NCT03406286</nct_id>
  </id_info>
  <brief_title>Samsca PMS in ADPKD Patients</brief_title>
  <official_title>Post-Marketing Surveillance of Safety and Efficacy of Samsca® Tablets in Korean Patients With ADPKD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is a Post-Marketing Surveillance study of Samsca® tablets in actual use in cases to slow
      the progression of cyst development and renal insufficiency in accordance with Korean
      regulations on Risk Management Plan(RMP) and New Drug Re-examination. This survey is a
      post-marketing, prospective, single-arm, all-cases survey conducted on approved indication,
      usage, dosage. The follow-up period shall basically start at the administration start and
      last until the end of the survey.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence rate and the number of Adverse Events (AE) / Adverse Drug Response (ADR)</measure>
    <time_frame>4 years</time_frame>
    <description>All adverse events (AEs) observed during/after the administration will be analyzed as safety assessment. The number of patients and the number of AE, ADR, Serious AE·ADR, Unexpected AE·ADR will be calculated (frequency and percentage).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of liver injury event</measure>
    <time_frame>4 years</time_frame>
    <description>the incidence rate of more than 3 times the upper limit of normal ALT or AST will be presented.
the incidence rate of more than 3 times the upper limit of normal ALT or AST and more than 2 times the upper limit of normal total bilirubin will be presented.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Safety</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <other_name>Samsca</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        At least 600 patients will be enrolled for survey period (4 years). Especially, Liver
        injury cases of all patients in actual use of Samsca® Tablets to slow the progression of
        cyst development and renal insufficiency will be focused on monitoring.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years and older patients with CKD stage 1 to 3 at initiation of treatment with
             evidence of rapidly progressing disease.

          2. Patients who need to be prescribed by Investigators who got registered in Risk
             Management Plan.

          3. Patients who have agreed and signed on conditions specified in Risk Management Plan.

        Exclusion Criteria:

          1. Patients with known or suspected hypersensitivity to tolvaptan or chemically related
             structures such as benzazepines (benzazapril or mirtazapine) or to any ingredient of
             the drug

          2. Patients requiring urgent intervention to raise serum sodium acutely.

          3. Inability of the patient to sense or appropriately respond to thirst.

          4. Hypovolemic hyponatremia

          5. Concomitant use of strong CYP3A inhibitors

          6. Anuric patients

          7. Volume depletion patients

          8. Hypernatremia patients

          9. Women who are pregnant or possibly pregnant and lactation

         10. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption

         11. Patients who are applicable to permanent discontinuation criteria prior to initiation
             of Samsca® Tablets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyo-Won Jeong</last_name>
    <email>jhw0159@otsuka.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kim Med Clinic</name>
      <address>
        <city>Miryang-si</city>
        <state>Gyeongsangnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>nephrologist</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>January 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 14, 2018</last_update_submitted>
  <last_update_submitted_qc>January 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post Marketing Surveillance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

